Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;42(3):309-323.
doi: 10.1016/j.cll.2022.04.004. Epub 2022 Aug 22.

Panel Sequencing for Targeted Therapy Selection in Solid Tumors

Nicholas Willard  1 , Lynette Sholl  2 , Dara Aisner  3
Affiliations
Review

Panel Sequencing for Targeted Therapy Selection in Solid Tumors

Nicholas Willard et al. Clin Lab Med. 2022 Sep.

Abstract

The genetic testing of solid tumors has evolved rapidly. With an ever-increasing number of clinically significant and/or actionable gene alterations in addition to increasing biologic, gene, or mutation-specific therapies, single-target testing is no longer suitable for many modern oncology patients. This review explores panel-based testing, including its history and evolution from prior testing modalities. We also discuss its current usefulness, as best exemplified by lung cancer, and other special considerations including a summary of the pros and cons of panel implementation and use. Lastly, we discuss the successes and challenges of panel-based testing and explore future directions.

Keywords: Next-generation sequencing (NGS); Panel; Sequencing; Solid tumor; Targeted; Therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr L. Sholl reports consulting income from Genentech and Lilly, and research funds from Genentech. Dr D. Aisner reports consulting income from Takeda, Sanofi-Genzyme, Loxo Oncology, and Blueprint Medicines.

Substances